Skip to main content

Table 1 Summary of efficacies and potencies of topotecan and indenoisoquinoline derivatives

From: Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome

Compound

EC50 [M]

Emax

LC50 [M]

Topotecan

3.04E−08 (± 3.40E−09)

1.51 (± 0.11)

2.30E−06 (± 2.01E−08)

Indotecan

2.56E−08 (± 1.05E−09)*

1.78 (± 0.13)*

2.01E−06 (± 1.59E−07)

Indimitecan

7.47E−09 (± 7.49E−10)*

1.47 (± 0.10)

7.89E−07 (± 3.43E−08)*

DB-IV-58

3.10E−08 (± 9.75E−09)

1.45 (± 0.12)

2.01E−06 (± 1.09E−07)

DB-V-37

2.99E−08 (± 8.29E−09)

1.48 (± 0.08)

2.02E−06 (± 1.02E−07)

  1. EC50, Emax, and LC50 are estimated from data presented in Fig. 4. Significance was tested by two-way ANOVA, followed by a Bonferroni correction for multiple comparisons to determine significant differences (*p < 0.05) from topotecan-treated neurons
Back to article page

Molecular Autism

ISSN: 2040-2392